David Dai
Stock Analyst
(n/a)
# 3,866
Out of 4,648 analysts
18
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMCR Immunocore Holdings | Initiates: Sell | $24 | $31.17 | -23.00% | 1 | Oct 24, 2024 | |
| NUVL Nuvalent | Initiates: Neutral | $100 | $89.53 | +11.69% | 1 | Oct 24, 2024 | |
| BPMC Blueprint Medicines | Initiates: Neutral | $88 | $91.88 | -4.22% | 1 | Oct 24, 2024 | |
| CATX Perspective Therapeutics | Initiates: Buy | $20 | $12.19 | +64.07% | 1 | Oct 24, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Buy | $35 | $25.04 | +39.78% | 1 | Oct 24, 2024 | |
| MRUS Merus | Initiates: Buy | $72 | $51.23 | +40.54% | 1 | Oct 24, 2024 | |
| KURA Kura Oncology | Initiates: Buy | $27 | $17.81 | +51.60% | 1 | Oct 24, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $69 | $55.87 | +23.50% | 1 | Oct 24, 2024 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | $50 | $30.00 | +66.67% | 1 | Oct 24, 2024 | |
| IOVA Iovance Biotherapeutics | Initiates: Buy | $17 | $11.44 | +48.60% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $15.92 | +88.44% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $36.78 | +63.13% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $18.94 | +95.35% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $1.26 | +2,122.22% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $15.55 | +157.23% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $3.70 | +981.08% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $3.23 | +1,447.99% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $39.86 | +30.46% | 1 | Mar 17, 2020 |
Immunocore Holdings
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $31.17
Upside: -23.00%
Nuvalent
Oct 24, 2024
Initiates: Neutral
Price Target: $100
Current: $89.53
Upside: +11.69%
Blueprint Medicines
Oct 24, 2024
Initiates: Neutral
Price Target: $88
Current: $91.88
Upside: -4.22%
Perspective Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $20
Current: $12.19
Upside: +64.07%
Nurix Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $35
Current: $25.04
Upside: +39.78%
Merus
Oct 24, 2024
Initiates: Buy
Price Target: $72
Current: $51.23
Upside: +40.54%
Kura Oncology
Oct 24, 2024
Initiates: Buy
Price Target: $27
Current: $17.81
Upside: +51.60%
Janux Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $55.87
Upside: +23.50%
IDEAYA Biosciences
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $30.00
Upside: +66.67%
Iovance Biotherapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $17
Current: $11.44
Upside: +48.60%
Oct 24, 2024
Initiates: Buy
Price Target: $30
Current: $15.92
Upside: +88.44%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $36.78
Upside: +63.13%
Oct 24, 2024
Initiates: Buy
Price Target: $37
Current: $18.94
Upside: +95.35%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $1.26
Upside: +2,122.22%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $15.55
Upside: +157.23%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $3.70
Upside: +981.08%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $3.23
Upside: +1,447.99%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $39.86
Upside: +30.46%